ESTRO 2023 - Abstract Book

S1053

Digital Posters

ESTRO 2023

Results We found 149 tumors in the 100 patients who met the requirements for this study. The average time to follow up was 22 months. The cumulative incidence of LF was 20% after 12 months and 35% after 24 months. The prescribed dose with BED > 100 Gy predicted a better LC, the 1-2 years LC were 82 and 72% respectively vs 75 and 58% for the BED <100 Gy. One- and two-year OS after SBRT were 70 and 48 % respectively. At 12 and 24 months, the cumulative rate of LF was much higher in patients with colorectal metastases (35% and 55%) than in NSCLC or any other cancer (p0.002). For colorectal metastases treated with BED10 > 100 Gy or < 100 Gy, the cumulative rates of LF after 24 months were 75% and 35%, respectively. Conclusion The efficacy of SBRT for metastatic lung cancers have been demonstrated by its good local control, treatment-free intervals, and overall survival (OS). Colorectal cancer metastases are the exception; they have a high LF rate that is compatible with a radioresistant phenotype, which may indicate a role in dose escalation 1 University Hospital Magdeburg, Department of Radiation Oncology, Magdeburg, Germany; 2 University Hospital Graz, Department of Radiation Oncology, Graz, Austria Purpose or Objective To find out the pattern of failure after lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). Materials and Methods Between 2010 and 2021, 124 NSCLC patients with 138 separate lesions were treated with SBRT at a single institution. Patients were put into three groups: Group 1 had people with early-stage local disease that had never been treated locally before. In-group 2, there was locally recurrent disease after local treatment of a primary lesion. In-group 3, the patients with oligoprogressive lung metastasis. Competing risk analysis was used for all time-to-event analyses. The Kaplan Meier method was used to figure out the local failure-free survival (LFFS), the nodal failure-free survival (NFFS), the progression free survival (PFS), and the overall survival (OS). Results At a median of 34 months of follow-up, 60% of the study population was still alive. The projected 3-year LFFS for patients in groups 1, 2, and 3 was 85%, 75 %, and 73 %, respectively. For each group, the estimated 3-year PFS was 75%, 55%, and 59%, while the projected 3-year OS was 45% (range: 41-82%), 44% (37-96%), and 65% (range: 31-100%). When corrected for age and lesion , there was no significant difference between groups in OS, LFFS, or PFS (p > 0.05), for LFFS, there was significant correlation with BED10>100 (p-value: 0.04). No patients experienced toxicity of grades 3 or 4 Conclusion Our data reveals control rates in group 1 patient’s equivalent to historical controls. Our study further demonstrates comparable clinical outcomes for SBRT in the treatment of NSCLC by demonstrating comparable rates of LFFS and OS in patients with locally recurrent and therapy-naive lung lesions and well-controlled distant metastatic disease in groups 2 and 3. 1 Oncology Service of Mother Teresa University Hospital, Radiation Oncology, Tirana, Albania; 2 Oncology Service of Mother Teresa University Hospital, Medical Oncology, Tirana, Albania Purpose or Objective Lung cancer is the second most common cancer and is by far the leading cause of cancer death. Most patients with non small cell lung cancer (NSCLC) are diagnosed at stage IV and approximately one third at stage III disease. Early-stage diagnosis is a challenge and is associated with improved survival, often providing the opportunity for cure. The aim of our study was to analyze the epidemiological, clinical and pathological characteristics of NSCLC in Albania. Materials and Methods The data of 225 Non-small Cell Lung Cancer (NSCLC) patients diagnosed in the Clinic of Oncology at University Hospital Center Mother Teresa, during 2016-2020 were retrospectively analyzed, to identify characteristics and pattern of lung cancer in Albania. Demographic, clinical and histopathological were reviewed. Statistical analysis was done using SPSS version 26 (SPSS, Chicago, IL). Results The patients’ mean age at the diagnosis was 64 years old (range 32-89 years) and the male to female rate was 11.6:1. Forty percent and 38,7% of the patients at the diagnosis were in the age group 66-75 and 56-65 years old respectively, and only 2,7% were under 45 years old. Eighty four percent of the patients had smoking history and of them only 4% were female. Main primary tumor location was in the right side, 61%. Squamous cell carcinoma was the main histopathologic type with 67%, adenocarcinoma 31% and 63 % of the cases were moderate differentiated. At the diagnosis 45.3% were stage III, 40% PO-1313 Failure patterns after stereotactic body radiation therapy for non-small-cell lung cancer A. Gawish 1 , B. Röllich 1 , M. Ha 1 , M. Walke 1 , T. Brunner 2 PO-1314 Epidemiological, clinical and pathological characteristics of non-small cell lung cancer in Albania E. Karaulli 1 , E. Kozma 1 , E. Abdiu 2 , B. Kreka 2 , A. Durbaku 2 , S. Senjo 2 , F. Kraja 1